Athersys Inc.

Athersys Inc. is a clinical-stage biotechnology company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for the cardiovascular, neurological, inflammatory and immune disease areas. The company currently has five clinical stage programs involving MultiStem, including those for treating inflammatory bowel disease (partnered with Pfizer Inc.), ischemic stroke, damage caused by myocardial infarction and for the prevention of graft-versus-host disease. Athersys has additional pharmaceutical programs in the metabolic and neurological areas, and a broad international network of collaborations with leading clinical and research institutions.

Expert Comments:

Jason Kolbert, Maxim Group (1/23/15)
"Athersys Inc. is closing in on a major milestone with stroke data from the MultiStem Phase 2 trial coming in Q1/15. . .good data in stroke should be transforming for the company and could drive a valuation inflection for investors. Moving MultiStem to the clinic for acute respiratory distress syndrome with nondilutive funding represents additional upside."

Henry McCusker, Regenerative Medicine Investors (1/22/15)
"Athersys Ltd. has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, to support a Phase 2a clinical study evaluating the administration of MultiStem cell therapy to acute respiratory distress syndrome patients. The grant is expected to provide up to approximately £2M in support over the course of the study. . .the company's stock should benefit as the costs of testing MultiStem will be supplemented."

"Athersys Inc. is studying MultiStem in human trials for stroke, myocardial infarction (MI) and graft-versus-host disease (GvHD). It is in Phase 2 development for stroke and early Phase 1 for MI and GvHD. The firm completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E. Athersys plans to progress its MI program into Phase 2 in Q1/15. The company is looking for a development partner to further its program. Announcing a partnership deal would signal investors that experts have faith in MultiStem, and Athersys' stock price would respond positively." read more >

Christian Glennie, Edison Investment Research (1/12/15)
"Enrolment in the potentially pivotal phase 2 study assessing Athersys Inc.'s MultiStem in ischaemic stroke patients is now complete. With a 90-day primary efficacy endpoint, headline data are expected towards the end of Q1/15. . .across the U.S., EU and Japan, we estimate peak sales of $3B."

Jason Kolbert, Maxim Group (12/29/14)
"Athersys Inc. is closing in on a major milestone. . .the company announced that it has concluded enrollment of its Phase 2 (~N=140) control versus active stroke trial. . .our research and channel checks leave us enthused about stroke data in Q1/15. We believe the probability skew is positive for Athersys, and the outcome has the potential to be transformative for both the company and patients."

Wall Street Titan, Seeking Alpha (11/26/14)
"Athersys Inc. is doing everything within its power to position itself to grab a Japanese revenue opportunity that would place an entirely new valuation on the company. The beauty of this legislation, from a risk perspective, is that Athersys does not need a home run from its stroke data to start earning substantial revenues in Japan. The company has already demonstrated safety. . .with an enterprise value of only $78M it certainly seems that Athersys shares have substantial room for upside, based on the stroke opportunity and their other programs entering phase 2 shortly, including graft-versus-host disease and acute myocardial infarction."

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Athersys Inc. Content